

Key #9
03 CD

Please place a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)



Application Number	10/058,821
Filing Date	January 29, 2002
First Named Inventor	Orest W. Blaschuk
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket No.	100086.401C12

ENCLOSURES (check all that apply)

- | | | |
|--|--|--|
| <input type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Assignment Papers
(for an Application) | <input type="checkbox"/> CD(s), Number
of CD(s) _____ |
| <input type="checkbox"/> Fee Attached | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> After Allowance
Communication to Group |
| <input type="checkbox"/> Amendment/Response | <input type="checkbox"/> Request for Corrected Filing
Receipt | <input type="checkbox"/> Appeal Communication to
Board of Appeals and
Interferences |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to
Group (Appeal Notice, Brief,
Reply Brief) |
| <input type="checkbox"/> Affidavits/declaration(s) | <input type="checkbox"/> Petition | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Petition to Convert to a
Provisional Application | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Express Abandonment
Request | <input type="checkbox"/> Power of Attorney,
Revocation, Change of
Correspondence Address | <input checked="" type="checkbox"/> Return Postcard |
| <input checked="" type="checkbox"/> Information Disclosure
Statement; Form PTO-1449 | <input type="checkbox"/> Declaration | <input type="checkbox"/> Additional Enclosure(s)
(please identify below): |
| <input checked="" type="checkbox"/> Cited References (4) | <input type="checkbox"/> Statement under 37 CFR
3.73(b) | _____ |
| <input type="checkbox"/> Certified Copy of Priority
Document(s) | <input type="checkbox"/> Terminal Disclaimer | _____ |
| <input type="checkbox"/> Response to Missing Parts
under 37 C.F.R. 1.52 or 1.53 | <input type="checkbox"/> Small Entity Statement | _____ |
| <input type="checkbox"/> Response to Missing
Parts/Incomplete Application | <input type="checkbox"/> Request for Refund | _____ |


Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	William T. Christiansen, Ph.D.	 00500 PATENT TRADEMARK OFFICE
Signature		
Date	5/6/02	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.

Typed or printed name	Nathan Adderson	
Signature		Date: 5/7/02



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Orest W. Blaschuk et al.
Application No. : 10/058,821
Filed : January 29, 2002
For : COMPOUNDS AND METHODS FOR CANCER
THERAPY

Docket No. : 100086.401C12
Date : May 7, 2002

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Forms PTO-1449. This application is a continuation and relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 09/357,717, filed July 20, 1999; which is a continuation-in-part of Application No. 09/248,074, filed February 10, 1999; which is a continuation-in-part of Application No. 08/996,679, filed December 23, 1997; which is a continuation-in-part of Application No. 08/893,534, filed July 11, 1997; which claims priority from U.S. Provisional Application No. 60/021,612, filed July 12, 1996.

References AP (on Page 1 of the attached Forms PTO-1449), BH (on Page 2 of the attached Forms PTO-1449), FC, and FG (on Page 6 of the attached Forms PTO-1449) were not submitted in these prior applications. Accordingly, copies of these references have been provided.

The references listed on the attached Forms PTO-1449 were submitted to and/or cited by the Patent and Trademark Office in this prior application and, therefore, are not required to be provided in this application. If the Examiner wishes, copies will be provided upon request.

As to any reference made of record on the attached Forms PTO-1449, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



William T. Christiansen, Ph.D.

Registration No. 44,614

WTC:nka

Enclosures:

Postcard

Form PTO/SB/21

Form PTO-1449

Cited References (4)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

D:\NrPortbl\iManage\NATHANA\279280_1.DOC

MAY 21 2002

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

MAY 21 2002

ATTY. DOCKET NO.

100886.401C12

APPLICATION NO.

10/058,821

Sheet 1 of 6

INFORMATION DISCLOSURE STATEMENT

(Use separate sheets if necessary)

APPLICANTS

Orest W. Blaschuk et al.

FILING DATE

January 29, 2002

GROUP ART UNIT

Not Yet Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,231,082	07/27/93	Schasteen	514	11	
	AB	5,352,667	10/04/94	Lider et al.	514	19	
	AC	5,510,628	04/23/96	Georger, Jr. et al.	257	32	
	AD	5,585,351	12/17/96	Ranscht	514	12	
	AE	5,591,432	01/07/97	Bronson et al.	424	130.1	
	AF	5,646,250	07/08/97	Suzuki	530	350	
	AG	5,665,590	09/09/97	Yang	435	6	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AH	EP 406 428 B1	01/09/91	EPO		
	AI	WO 91/04745	04/18/91	PCT		
	AJ	WO 92/08731	05/29/92	PCT		
	AK	WO 94/11401	05/26/94	PCT		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AL	Alexander et al., "An N-Cadherin-Like Protein Contributes to Solute Barrier Maintenance in Cultured Endothelium," <i>Journal of Cellular Physiology</i> 156: 610-618, 1993.
	AM	Ali et al., "Conformationally Constrained Peptides and Semipeptides Derived from RGD as Potent Inhibitors of the Platelet Fibrinogen Receptor and Platelet Aggregation," <i>J. Med. Chem.</i> 37(6): 769-780, 1994.
	AN	Beesley et al., "The post-synaptic density: putative involvement in synapse stabilization via cadherins and covalent modification by ubiquitination," <i>Biochemical Society Transactions</i> 23: 59-64, 1995.
	AO	Blakemore, "Remyelination of CNS axons by Schwann cells transplanted from the sciatic nerve," <i>Nature</i> 266: 68-69, 1977.
	AP	Blaschuk et al., "A novel cadherin antagonist (Exherin) blocks human ovarian tumor growth in nude mice," <i>Molecular Biology of the Cell</i> 10: 72A, November 1999.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)

MAY 2 1 2002

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
100086.401C12APPLICATION NO.
10/058,821

INFORMATION DISCLOSURE STATEMENT

(Use additional sheets if necessary)

APPLICANTS

Orest W. Blaschuk et al.

FILING DATE

January 29, 2002

GROUP ART UNIT

Not Yet Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA	6,031,072					
	BB	6,169,071					
	BC	6,207,639					

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BD	WO 96/40781	12/19/96	PCT		
	BE	WO 97/07209	02/27/97	PCT		
	BF	WO 98/02452	01/22/98	PCT		
	BG	WO 98/45319	10/15/98	PCT		
	BH	WO 99/33875	7/8/99	WIPO		


OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BI	Blaschuk and Farookhi, "Estradiol Stimulates Cadherin Expression in Rat Granulosa Cells," <i>Developmental Biology</i> 136: 564-567, 1989.
	BJ	Blaschuk et al., "E-Cadherin, estrogens and cancer: is there a connection?" <i>The Canadian Journal of Oncology</i> 4(4): 291-301, 1994.
	BK	Blaschuk et al., "Identification of a Cadherin Cell Adhesion Recognition Sequence," <i>Developmental Biology</i> 139: 227-229, 1990.
	BL	Blaschuk et al., "Identification of a Conserved Region Common to Cadherins and Influenza Strain A Hemagglutinins," <i>J. Mol. Biol.</i> 211: 679-682, 1990.
	BM	Bottenstein and Sato, "Growth of a rat neuroblastoma cell line in serum-free supplemented medium," <i>Proc. Natl. Acad. Sci. USA</i> 76(1): 514-517, 1979.
	BN	Brecknell et al., "Bridge grafts of Fibroblast Growth Factor-4-Secreting Schwannoma Cells Promote Functional Axonal Regeneration in the Nigrostriatal Pathway of the Adult Rat," <i>Neuroscience</i> 74(3): 775-784, 1996.
	BO	Brockes et al., "Studies on Cultured Rat Schwann Cells. I. Establishment of Purified Populations from Cultures of Peripheral Nerve," <i>Brain Research</i> 165: 105-118, 1979.
	BP	Brook et al., "Morphology and Migration of Cultured Schwann Cells Transplanted Into the Fimbria and Hippocampus in Adult Rats," <i>GLIA</i> 9: 292-304, 1993.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
100086.401C12APPLICATION NO.
10/058,821

INFORMATION DISCLOSURE STATEMENT

(Use Transparencies if necessary)

APPLICANTS
Orest W. Blaschuk et al.FILING DATE
January 29, 2002GROUP ART UNIT
Not Yet Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	-----------------	------	------	-------	----------	-------------------------------

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
-----------------	------	---------	-----------------------


OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Byers et al., "Fibroblast Growth Factor Receptors Contain a Conserved HAV Region Common to Cadherins and Influenza Strain A Hemagglutinins: A Role in Protein-Protein Interactions?," <i>Developmental Biology</i> 152: 411-414, 1992.
CB	Cardarelli et al., "The Collagen Receptor $\alpha 2\beta 1$, from MG-63 and HT1080 Cells, Interacts with a Cyclic RGD Peptide," <i>The Journal of Biological Chemistry</i> 267(32): 23159-23164, 1992.
CC	Carlstedt et al., "Nerve Fibre Regeneration Across the PNS-CNS Interface at the Root-Spinal Cord Junction," <i>Brain Research Bulletin</i> 22: 93-102, 1989.
CD	Cepek et al., "Expression of a candidate cadherin in T lymphocytes," <i>Proc. Natl. Acad. Sci. USA</i> 93: 6567-6571, 1996.
CE	Chuah et al., "Differentiation and survival of rat olfactory epithelial neurons in dissociated cell culture," <i>Developmental Brain Research</i> 60: 123-132, 1991.
CF	Craig et al., "Concept and Progress in the Development of RGD-Containing Peptide Pharmaceuticals," <i>Biopolymers (Peptide Science)</i> 37: 157-175, 1995.
CG	Doherty and Walsh, "CAM-FGF Receptor Interactions: A Model for Axonal Growth," <i>Molecular and Cellular Neuroscience</i> 8(Article No. 0049): 99-111, 1996.
CH	Doherty and Walsh, "Signal transduction events underlying neurite outgrowth stimulated by cell adhesion molecules," <i>Current Opinion in Neurobiology</i> 4: 49-55, 1994.
CI	Doherty et al., "Neurite Outgrowth in Response to Transfected N-CAM and N-Cadherin Reveals Fundamental Differences in Neuronal Responsiveness to CAMS," <i>Neuron</i> 6: 247-258, 1991.
CJ	Duncan et al., "Transplantation of oligodendrocytes and Schwann cells into the spinal cord of the myelin-deficient rat," <i>Journal of Neurocytology</i> 17: 351-360, 1988.
CK	Fok-Seang et al., "An analysis of astrocytic cell lines with different abilities to promote axon growth," <i>Brain Research</i> 689: 207-223, 1995.
CL	Fok-Seang et al., "Migration of Oligodendrocyte Precursors on Astrocytes and Meningeal Cells," <i>Developmental Biology</i> 171: 1-15, 1995.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 100086.401C12		APPLICATION NO. 10/058,821	
 <p>INFORMATION DISCLOSURE STATEMENT (See 37 CFR 1.102(b) for filing requirements)</p>				APPLICANTS Orest W. Blaschuk et al.			
				FILING DATE January 29, 2002		GROUP ART UNIT Not Yet Assigned	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	DA	Franz, "Percutaneous Absorption. On The Relevance Of In Vitro Data," <i>The Journal of Investigative Dermatology</i> 64(3): 190-195, 1975.					
	DB	Franz, "The Finite Dose Technique as a Valid <i>in Vitro</i> Model for the Study of Percutaneous Absorption in Man," <i>Curr. Probl. Dermatol.</i> 7: 58-68, 1978.					
	DC	Ghirnikar and Eng, "Astrocyte-Schwann Cell Interactions in Culture," <i>GLIA</i> 11: 367-377, 1994.					
	DD	Gumbiner et al., "The Role of the Cell Adhesion Molecule Uvomorulin in the Formation and Maintenance of the Epithelial Junctional Complex," <i>The Journal of Cell Biology</i> 107: 1575-1587, 1988.					
	DE	Iruela-Arispe et al., "Expression of SPARC during Development of the Chicken Chorioallantoic Membrane: Evidence for Regulated Proteolysis In Vivo," <i>Molecular Biology of the Cell</i> 6: 327-343, 1995.					
	DF	Laird et al., "Gap Junction Turnover, Intracellular Trafficking, and Phosphorylation of Connexin43 in Brefeldin A-treated Rat Mammary Tumor Cells," <i>The Journal of Cell Biology</i> 131(5): 1193-1203, 1995.					
	DG	Lee et al., "Expression of the Homotypic Adhesion Molecule E-Cadherin by Immature Murine Thymocytes and Thymic Epithelial Cells," <i>Journal of Immunology</i> 152: 5653-5659, 1994.					
	DH	Letourneau et al., "Interactions of Schwann Cells with Neurites and with Other Schwann Cells Involve the Calcium-dependent Adhesion Molecule, N-cadherin," <i>Journal of Neurobiology</i> 22(7): 707-720, 1991.					
	DI	Liuzzi and Lasek, "Astrocytes Block Axonal Regeneration in Mammals by Activating the Physiological Stop Pathway," <i>Science</i> 237: 642-645, 1987.					
	DJ	Lutz et al., "Secondary Structure of the HAV Peptide Which Regulates Cadherin-Cadherin Interaction," <i>Journal of Biomolecular Structure & Dynamics</i> 13(3): 447-455, 1995.					
	DK	Matsuzaki et al., "cDNAs of Cell Adhesion Molecules of Different Specificity Induce Changes in Cell Shape and Border Formation in Cultured S180 Cells," <i>The Journal of Cell Biology</i> 110: 1239-1252, 1990.					
EXAMINER				DATE CONSIDERED			
<p>* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).</p>							

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
100086.401C12APPLICATION NO.
10/058,821

INFORMATION DISCLOSURE STATEMENT

MAY 21 2002

(Use several sheets if necessary)

APPLICANTS
Orest W. Blaschuk et al.FILING DATE
January 29, 2002GROUP ART UNIT
Not Yet Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	-----------------	------	------	-------	----------	-------------------------------

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
-----------------	------	---------	-----------------------

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EA	McCarthy and Vellis, "Preparation of Separate Astroglial and Oligodendroglial Cell Cultures from Rat Cerebral Tissue," <i>J. Cell Biology</i> 85: 890-902, 1980.
EB	Mege et al., "Construction of epithelioid sheets by transfection of mouse sarcoma cells with cDNAs for chicken cell adhesion molecules," <i>Proc. Natl. Acad. Sci. USA</i> 85: 7274-7278, 1988.
EC	Moran, "The Protein Delivery Service. Advances in technologies for delivering proteins and peptides in therapeutically useful forms," <i>Pharmaceutical Forum Issue</i> 6: 4-7, 1996.
ED	Munro and Blaschuk, <i>Cell Adhesion and Invasion in Cancer Metastasis</i> , R.G. Landes Company, Austin, TX, 1996, Chapter 3, "The Structure, Function and Regulation of Cadherins," pp. 17-34.
EE	Munro et al., "Characterization of Cadherins Expressed by Murine Thymocytes," <i>Cellular Immunology</i> 169(Article No. 0123): 309-312, 1996.
EF	Newton et al., "N-Cadherin Mediates Sertoli Cell-Spermatogenic Cell Adhesion," <i>Developmental Dynamics</i> 197: 1-13, 1993.
EG	Nose et al., "Localization of Specificity Determining Sites in Cadherin Cell Adhesion Molecules," <i>Cell</i> 61: 147-155, 1990.
EH	Orr, "Angiogenesis Research Offers New Approaches to Treatment of Disease," <i>Genetic Engineering News</i> , pp. 15-16, 42, May 1, 1996.
EI	Overduin et al., "Solution Structure of the Epithelial Cadherin Domain Responsible for Selective Cell Adhesion," <i>Science</i> 267: 386-389, 1995.
EJ	Redies and Takeichi, "Cadherins in the Developing Central Nervous System: An Adhesive Code for Segmental and Functional Subdivisions," <i>Developmental Biology</i> 180: 413-423, 1996.
EK	Saffell et al., "Expression of a Dominant Negative FGF Receptor Inhibits Axonal Growth and FGF Receptor Phosphorylation Stimulated by CAMs," <i>Neuron</i> , pp. 231-242, February 1997.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
100086.401C12APPLICATION NO.
10/058,821

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS
Orest W. Blaschuk et al.FILING DATE
January 29, 2002GROUP ART UNIT
Not Yet Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	-----------------	------	------	-------	----------	-------------------------------

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
-----------------	------	---------	-----------------------

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

FA	Samanen et al., "Development of a Small RGD Peptide Fibrinogen Receptor Antagonist with Potent Antiaggregatory Activity in Vitro," <i>J. Med. Chem.</i> 34(10): 3114-3125, 1991.
FB	Shapiro et al., "Structural basis of cell-cell adhesion by cadherins," <i>Nature</i> 374: 327-337, 1995.
FC	Starzinsky-Powitz, E.A., "The putative role of cell adhesion molecules in endometriosis," <i>Mol. Med. Today</i> 5(7): 304-309, 1999.
FD	Tsutsui et al., "Expression of Cadherin-Catenin Complexes in Human Leukemia Cell Lines," <i>J. Biochem.</i> 120: 1034-1039, 1996.
FE	Wickelgren, "Breaking the Skin Barrier," <i>PS</i> 12: 86-88, 1996.
FF	Willems et al., "Cadherin-dependent cell aggregation is affected by decapeptide derived from rat extracellular super-oxide dismutase," <i>FEBS Letters</i> 363: 289-292, 1995.
FG	Williams, E.A., "A novel family of cyclic peptide antagonists suggests that N-cadherin specificity is determined by amino acids that flank the HAV motif," <i>J. Biol. Chem.</i> 275(6): 4007-4012, February 11, 2000.
FH	Williams et al., "Activation of the FGF Receptor Underlies Neurite Outgrowth Stimulated by L1, N-CAM, and N-Cadherin," <i>Neuron</i> 13: 583-594, 1994.
FI	Williams et al., "The Primary Structure of Hen Ovotransferrin," <i>Eur. J. Biochem.</i> 122: 297-303, 1982.
FJ	
FK	
FL	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).